A novel report of nivolumab-induced transient and persistent acantholytic dermatosis associated with multiple cutaneous toxicities in a patient with metastatic melanoma

References

• Wongvibulsin S, Pahalyants V, Kalinich M, et al. Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: a United States population-level analysis. J Am Acad Dermatol. 2021;86(3):563–572.
   PubMedGoogle Scholar
• Bellinato F, Maurelli M, Gisondi P, et al. Clinical features and treatments of transient acantholytic dermatosis (Grover’s disease): a systematic review. J Dtsch Dermatol Ges. 2020;18(8):826–833.
   Google Scholar
• Uemura M, Fa'ak F, Haymaker C, et al. A case report of grover’s disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1. J Immunother Cancer. 2016;4:55.
   PubMed Web of Science ®Google Scholar
• Koelzer VH, Buser T, Willi N, et al. Grover’s-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy. J Immunother Cancer. 2016;4:47.
   PubMed Web of Science ®Google Scholar
• Munoz J, Guillot B, Girard C, et al. First report of ipilimumab-induced grover disease. Br J Dermatol. 2014;171(5):1236–1237.
   PubMed Web of Science ®Google Scholar
• Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol. 2016;2(10):1346–1353.
   PubMed Web of Science ®Google Scholar
• Apalla Z, Papageorgiou C, Lallas A, et al. Cutaneous adverse events of immune checkpoint inhibitors: a literature review. Dermatol Pract Concept. 2021;11(1):e2021155.
   PubMedGoogle Scholar
• Rambhia PH, Honda K, Arbesman J. Nivolumab induced inflammation of seborrheic keratoses: a novel cutaneous manifestation in a metastatic melanoma patient. Melanoma Res. 2018;28(5):475–477.
   PubMed Web of Science ®Google Scholar
• Bednarek R, Marks K, Lin G. Eruptive keratoacanthomas secondary to nivolumab immunotherapy. Int J Dermatol. 2018;57(3):e28–e9.
   PubMed Web of Science ®Google Scholar
• Fujimura T, Lyu C, Tsukada A, et al. Eruptive keratoacanthoma with spontaneous regression arising from a cervical squamous cell carcinoma patient treated with nivolumab. J Dermatol. 2019;46(5):e177–e8.
   PubMed Web of Science ®Google Scholar
• Horn TD, Groleau GE. Transient acantholytic dermatosis in immunocompromised febrile patients with cancer. Arch Dermatol. 1987;123(2):238–240.
   PubMedGoogle Scholar
• Guana AL, Cohen PR. Transient acantholytic dermatosis in oncology patients. J Clin Oncol. 1994;12(8):1703–1709.
   PubMed Web of Science ®Google Scholar
• Harvell JD, Hashem C, Williford PL, et al. Grover’s-like disease in the setting of bone marrow transplantation and autologous peripheral blood stem cell infusion. Am J Dermatopathol. 1998;20(2):179–184.
   PubMed Web of Science ®Google Scholar
• Cohen PR, Kurzrock R. Transient acantholytic dermatosis after treatment with 2-chlorodeoxyadenosine. Acta Derm Venereol. 1997;77(5):412–413.
   PubMed Web of Science ®Google Scholar
• Bolanos-Meade J, Anders V, Wisell J, et al. Grover’s disease after bone marrow transplantation. Biol Blood Marrow Transplant. 2007;13(9):1116–1117.
   PubMed Web of Science ®Google Scholar
• Ippoliti G, Paulli M, Lucioni M, et al. Grover’s disease after heart transplantation: a case report. Case Rep Transplant. 2012;2012:126592.
   PubMedGoogle Scholar
• Gantz M, Butler D, Goldberg M, et al. Atypical features and systemic associations in extensive cases of grover disease: a systematic review. J Am Acad Dermatol. 2017;77(5):952–957 e1.
   PubMed Web of Science ®Google Scholar
• Anforth RM, Blumetti TC, Kefford RF, et al. Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. Br J Dermatol. 2012;167(5):1153–1160.
   PubMed Web of Science ®Google Scholar
• Gupta M, Huang V, Cornelius LG. L. Unusual complication of vemurafenib treatment of metastatic melanoma: exacerbation of acantholytic dyskeratosis complicated by kaposi varicelliform eruption. Arch Dermatol. 2012;148(8):966–968.
   PubMedGoogle Scholar
• Carlos G, Anforth R, Clements A, et al. Cutaneous toxic effects of BRAF inhibitors alone and in combination with MEK inhibitors for metastatic melanoma. JAMA Dermatol. 2015;151(10):1103–1109.
   PubMed Web of Science ®Google Scholar
• Butler DC, Kollhoff A, Berger T. Treatment of grover disease with dupilumab. JAMA Dermatol. 2021;157(3):353–356.
   PubMed Web of Science ®Google Scholar
• Dulos J, Carven GJ, van Boxtel SJ, et al. PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer. J Immunother. 2012;35(2):169–178.
   PubMed Web of Science ®Google Scholar